TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02193009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SipSmarter
Description: 6-month behavioral trial

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MoveMore
Description: 6 month behavioral trial
Study: NCT04930835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant supported dentures
Description: Placement of dental implants with different loading protocols for supporting full arch dentures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant supported dentures
Description: Placement of dental implants with different loading protocols for supporting full arch dentures.
Study: NCT04009018

Intervention type: OTHER
Group type: OTHER
Intervention: Perioperative Satisfaction Scale in Regional Anesthesia
Description: This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
Study: NCT03955783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given by mouth
Study: NCT02709512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 plus Pem Platinum
Description: Investigational Drug in combination approved standard of care treatment for this indication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Pem Platinum
Description: Placebo in combination approved standard of care treatment for this indication
Study: NCT01144624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773
Description: A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of a saline solution
Study: NCT01876303

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02678403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
Study: NCT00632775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids
Description: Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids
Description: Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg.
Study: NCT00456755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shi-Bi-Lin
Description: 4 weeks of treatment, dose of 1 g (two capsules), twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
Study: NCT01999244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventionist Contact
Study: NCT04368013

Intervention type: PROCEDURE
Intervention: Extended sampling and procedures
Description: The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
Study: NCT04213183

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatobiliary Disorders
Description: The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatobiliary Disorders
Description: The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatobiliary Disorders
Description: The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
Study: NCT01350011

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Innovative System
Description: In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Control (STC)
Description: Participants will receive self help information and referrals for counseling and for pharmacological treatment.
Study: NCT03818711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication & Coping Intervention
Description: Mothers receive a treatment manual and participate in individual phone calls aimed at reducing depressive symptoms and improving the quality of parental involvement. A concurrent secret Facebook group will have daily posts to reinforce concepts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education & Check Ins
Description: Mothers receive educational materials and participate in individual phone calls related to these materials. A concurrent secret Facebook group will have daily educational posts.
Study: NCT02169713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral
Study: NCT02886910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical observation
Description: Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical observation
Description: Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard management
Description: Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
Study: NCT04879108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation
Description: Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Rehabilitation
Description: Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day.
Study: NCT01266278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound
Description: Measurement of the size of the subacromial space with dynamic ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FASTRAK
Description: Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of shoulder posture by measuring
Description: Assessment of shoulder posture by measuring several angles and distances.
Study: NCT02169713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT01455233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: besivance
Description: topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vigamox
Description: topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
Study: NCT01700881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supplement
Description: Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
Study: NCT03969836

Intervention type: DEVICE
Intervention: NeurOS system
Description: NeurOS system pads will be placed on patients' head for monitoring.
Study: NCT03242590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1021
Description: Oral testosterone undecanoate
Study: NCT03766464

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of TMD and pain sensitivity
Description: Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of SB
Description: The presence or absence of SB will be diagnosed by Polysomnography

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of AB
Description: A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
Study: NCT04072835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS
Description: Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
Study: NCT02944721

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetical analyses
Study: NCT01998958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: 1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study: NCT02272634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPL-001 160 mg
Description: twice daily \[BID\]
Study: NCT02944721

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetical analyses

Intervention type: OTHER
Group type: OTHER
Intervention: Chronic pain identification questionnaires

Intervention type: OTHER
Group type: OTHER
Intervention: Chronic pain identification questionnaires

Intervention type: OTHER
Group type: OTHER
Intervention: Neurophysiological and psychophysical evaluations

Intervention type: OTHER
Group type: OTHER
Intervention: Neurophysiological and psychophysical evaluations

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaires

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaires
Study: NCT01785927

Intervention type: OTHER
Group type: OTHER
Intervention: ABCD
Description: Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
Study: NCT00776698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80mg/m2 iv every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
Study: NCT01998958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: 1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine 56 mg
Description: 1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
Study: NCT00360685

Intervention type: DRUG
Group type: OTHER
Intervention: Tac+MTX
Description: Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
Study: NCT02272634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily \[BID\]
Study: NCT03764761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAC Technology - Standard of Care
Description: Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAC Technology - non-optimal integrated arrangement
Description: Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAC Technology - non-optimal integrated arrangement
Description: Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
Study: NCT01023191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Insertion catheter
Description: Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open insertion Catheter
Description: Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
Study: NCT00237913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine or Quetiapine or Risperidone
Description: Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
Study: NCT04460859

Intervention type: OTHER
Intervention: Specific lung recruitment maneuvers
Description: Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
Study: NCT05671016

Intervention type: PROCEDURE
Intervention: MRI scans and questionnaires
Description: Extra baseline MRI scan performed and questionnaires (EORTC validated questionnaires involving EORTC QLQ C-30, EORTC BN20 and EORTC ELD14) to assess quality of life at baseline, 4 weeks and 8 weeks after treatment
Study: NCT00611481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: a set of pre-designed Tai Chi Movements

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Lower-extremity strength training exercises

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low-Impact Exercise Control
Description: a set of chair-based low-impact exercises
Study: NCT04796753

Intervention type: OTHER
Intervention: Basketball Injury Defense
Description: To establish a specific evaluation protocol for youth basketball players.
Study: NCT01096030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: 160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
Study: NCT05041881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal lens AT LISA TRI, Zeiss
Description: lens is made of hydrophilic acrylic material with square edge technology and having diffractive optic design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accommodating Tetraflex HD lens, Lenstec inc.
Description: lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal lens, Softec HD
Description: lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
Study: NCT03246126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant™Thoracoabdominal Stent Graft System
Description: The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant™Thoracoabdominal Stent Graft System
Description: The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
Study: NCT00005614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride
Description: Gemcitabine via IV
Study: NCT03253835

Intervention type: DIAGNOSTIC_TEST
Intervention: Single Group Assignment

Intervention type: DIAGNOSTIC_TEST
Intervention: Single Group Assignment
Study: NCT02191631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy
Description: The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
Study: NCT00360685

Intervention type: DRUG
Group type: OTHER
Intervention: TAC + MMF
Description: Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
Study: NCT00044655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: As prescribed by routine prescriber (not dictated by study protocol)
Study: NCT01406483

Intervention type: OTHER
Group type: OTHER
Intervention: Platelet reactivity assessment
Description: Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.